Get startedLog in
    Picture of Silence Therapeutics logo

    SLNCF — Silence Therapeutics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMid CapMomentum Trap
    All News

    Brief: Silence Therapeutics Initiates Dosing In Phase 1 Clinical Trial Of Sln360 For Cardiovascular Disease

    Picture of Silence Therapeutics logoSilence Therapeutics
    17/02/2021 07:28
    Feb 17 (Reuters) - Silence Therapeutics PLC  SLN.L :
    * SILENCE THERAPEUTICS PLC - INITIATES DOSING IN PHASE 1
CLINICAL
TRIAL OF SLN360 FOR CARDIOVASCULAR DISEASE DUE TO HIGH
LIPOPROTEIN(A)

Source text for Eikon:  ID:nRSQ3950Pa 
Further company coverage:  SLN.L 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Silence Therapeutics

    See all news